Trial Profile
Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomatic> = 75 years.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Velcadito
- 14 Jan 2020 Status changed to discontinued.
- 06 Dec 2016 Results (n=26) of a retrospective analysis in newly diagnosed MM patients not eligible to transplant, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 27 Feb 2015 New trial record